Table 3.

Additive model ^*

Comparison	First-line therapy, OR (95% CI)	Salvage therapy, OR (95% CI)
KA/VE vs CVD	0.63 (0.14 to 2.12)	0.96 (0.42 to 1.91)
TEC vs CVD	1.79 (0.60 to 6.42)	0.77 (0.33 to 1.55)
TEE vs CVD	1.57 (0.47 to 6.18)	0.54 (0.26 to 0.86)
TEC vs KA/VE	2.85 (0.90 to 13.14)	0.80 (0.36 to 1.81)
TEE vs KA/VE	2.49 (0.73 to 12.60)	0.56 (0.30 to 0.94)
TEE vs TEC	0.87 (0.24 to 3.27)	0.70 (0.35 to 1.20)

^*Odds ratio (OR) estimates for the six possible regimen comparisons for both the first-line and the salvage setting along with 95% bootstrap confidence intervals (CIs) are shown. The four candidate drug regimens are cyclophosphamide, vincristine, and dexamethasone (CVD); ketoconazole plus doxorubicin alternating with vinblastine plus estramustine (KA/VE); paclitaxel, estramustine, and carboplatin (TEC); and paclitaxel, estramustine, and etoposide (TEE). The data used in this analysis were obtained directly from Thall et al. (1).